Literature DB >> 26815661

Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Mehmet Kanter1, Gulay Turan2, Ceyda Usta3, Akin Usta3, H Hasan Esen2, Lema Tavlı2, Cetin Celik4, Yusuf Demirkol5, Betül Kanter6.   

Abstract

The most prevalent malignant ovarian neoplasms are epithelial ovarian cancers which is the most common cause of death among all gynecologic malignancies and a result of complex interaction of multiple oncogenes and tumor suppressor genes. The aim of this study was to evaluate expression of survivin and cycline D1 biomarkers in mucinous ovarian neoplasms and their correlations with clinicopathological variables in mucinous ovarian cancers. We analyzed pathological specimens of 98 patients with benign (n = 34), borderline (n = 22) and malignant (n = 42) mucinous ovarian neoplasms. Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded specimens. Immunohistochemical analysis revealed that survivin and cyclin D1 expressions were located primarily in the nucleus of ovarian tumor cells and relatively weaker cytoplasmic staining. Survivin expression was significantly higher in malignant tumors (88.1 %) than those found in borderline (18.2 %) and benign tumors (8.8 %) (p < 0.001). Similarly, higher cyclin D1 expression was observed in malignant tumors (100 %) compared to borderline (36.4 %) and benign tumors (5.9 %) (p < 0.001). Expression of all biomarkers analyzed significantly and gradually increased from benign to borderline and borderline to malignant mucinous tumors. In terms of clinicopathological variables, tumor grade, FIGO stage and lymph node methastasis were associated with the expression of both biomarkers. Whereas age exhibited no different correlations in mucinous ovarian cancers. The expressions of survivin and cycline D1 are positively correlated with the malignant potential of mucinous ovarian neoplasms.

Entities:  

Keywords:  Cycline D1; Immunohistochemical analysis; Mucinous; Ovarian neoplasms; Survivin

Mesh:

Substances:

Year:  2016        PMID: 26815661     DOI: 10.1007/s10735-016-9661-8

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  36 in total

1.  Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma.

Authors:  Xueya Qian; Xiaowei Xi; Linxia Li
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-03

Review 2.  The case for survivin as a regulator of microtubule dynamics and cell-death decisions.

Authors:  Dario C Altieri
Journal:  Curr Opin Cell Biol       Date:  2006-08-24       Impact factor: 8.382

3.  Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Ilvars Silins; Kristiane Haug; Claes G Trope; Jahn M Nesland; Ben Davidson
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

4.  Clinical significance of nucleostemin expression and its correlation with cyclin D1 expression in malignant ovarian tumors.

Authors:  Sun Lin; Han Shi Yu
Journal:  Int J Gynecol Cancer       Date:  2011-10       Impact factor: 3.437

5.  Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma.

Authors:  Noriyuki Takai; Tami Miyazaki; Masakazu Nishida; Kaei Nasu; Isao Miyakawa
Journal:  Cancer Lett       Date:  2002-10-08       Impact factor: 8.679

6.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

7.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

8.  Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma.

Authors:  Noriyuki Takai; Tami Miyazaki; Masakazu Nishida; Kaei Nasu; Isao Miyakawa
Journal:  Int J Mol Med       Date:  2002-08       Impact factor: 4.101

Review 9.  The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention.

Authors:  John P Alao
Journal:  Mol Cancer       Date:  2007-04-02       Impact factor: 27.401

10.  Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters.

Authors:  G Ferrandina; F Legge; E Martinelli; F O Ranelletti; G F Zannoni; L Lauriola; M Gessi; V Gallotta; G Scambia
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

View more
  4 in total

1.  Differential Expression of Potential Biomarkers of Oral Squamous Cell Carcinoma Development.

Authors:  Paola Fernandes Pansini; Isabella Bittencourt do Valle; Thabata Coeli Dias Damasceno; Priscila Marinho de Abreu; Anna Clara Gregório Có; Rossana Verónica Mendoza López; Jeferson Lenzi; Ricardo Mai Rocha; Evandro Duccini Souza; Maria Paula Curado; Hisham Mehanna; Paul Nankivell; José Roberto Vasconcelos de Podestá; Sandra Ventorin von Zeidler
Journal:  Head Neck Pathol       Date:  2021-04-11

2.  Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.

Authors:  Xiaoyan He; Kehu Yang; Hailin Wang; Xiaohong Chen; Huifang Wu; Liang Yao; Shouye Ma
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

3.  Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle, apoptosis and autophagy of cancer cells.

Authors:  Fabiao Hu; Daxia Pan; Wenyun Zheng; Ting Yan; Xiujuan He; Fuzheng Ren; Yiming Lu; Xingyuan Ma
Journal:  Oncotarget       Date:  2017-12-01

Review 4.  The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.

Authors:  Yu Sun; Juan Xu; Xuemei Jia
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.